Boost to melanoma support in WA
31 January 2020
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
One Australian dies from melanoma every five hours and WA is second only to QLD in terms of melanoma incidence across Australia.
Chairman of melanomaWA, Martin Slabbert, said the merger with Melanoma Institute Australia was exciting and would have widespread benefits for the entire West Australian community.
‘The two highly respected organisations will be working together on a regional and national level regarding awareness, education, support, and research,’ Mr Slabbert said.
‘Importantly, the alignment will also provide local, regional, and remote melanoma patients with greater access to medical specialists through Melanoma Institute Australia’s network. This coordinated approach has been well received by patients connected with melanomaWA.’
CEO of Melanoma Institute Australia, Matthew Browne, said the merger would ensure increased resources dedicated to reducing the impact of melanoma on the community in WA.
‘Melanoma Institute Australia is delighted to be merging with melanomaWA,’ Mr Browne said. ‘Melanoma is, unfortunately, Australia’s national cancer and accordingly combining organisations from west coast and the east coast gives us all the best chance of fighting this disease.
‘Joining two strong melanoma organisations immediately brings increased resources and services to melanoma patients as well as a broader coordinated reach in raising awareness about early detection and prevention strategies including sun safety.’
The first fundraising and awareness event of the combined entity will be Melanoma March which will be held in Bunbury on 15th March and at Perth’s Cottesloe Beach on 29th March. Funds raised from the family-friendly Melanoma March events will support melanoma research to pave the way for new and life-saving treatments.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.